Showing results (1-10 of 100) with videos related to
Sort By:
Pageof 10
Arthritis & Rheumatology (Hoboken, N.J.)|July 21, 2025
B cells and systemic sclerosis interstitial lung diseaseNina Goldman, Voon Ong, Christopher DentonFrontiers in Immunology|May 23, 2022
The Yin and Yang of IL-17 in Systemic SclerosisLanxuan Wei, David Abraham, Voon OngPharmacology Research & Perspectives|November 26, 2019
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacyLynn Miesel, Kun-Yuan Lin, Voon OngBMJ Case Reports|April 1, 2014
Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonistsTanaka Ngcozana, Voon Ong, Christopher Paul DentonMicrobiology Spectrum|May 8, 2023
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of InvestigationsShawn Flanagan, Helen Walker, Voon Ong, et al.Antimicrobial Agents and Chemotherapy|December 7, 2016
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy AdultsTaylor Sandison, Voon Ong, Jonathan Lee, et al.Clinical and Experimental Rheumatology|November 6, 2014
Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosisNavjyot Hansi, Nora Thoua, Maresa Carulli, et al.Antimicrobial Agents and Chemotherapy|March 21, 2018
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 DataElizabeth A Lakota, Voon Ong, Shawn Flanagan, et al.Antimicrobial Agents and Chemotherapy|October 18, 2021
Metabolism, Excretion, and Mass Balance of [14C]-Rezafungin in Animals and HumansVoon Ong, Sarah Wills, Deborah Watson, et al.Antimicrobial Agents and Chemotherapy|February 1, 2017
Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal SpeciesVoon Ong, Kenneth D James, Steven Smith, et al.Pageof 10